Document is current
Any future updates will be listed below
-
Authors
Van Belle, Hannah https://orcid.org/0000-0001-8897-4229
Hurvitz, Sara A. https://orcid.org/0000-0001-7808-7191
Gilbar, Peter J. https://orcid.org/0000-0001-7748-1891
Wildiers, Hans https://orcid.org/0000-0001-8990-7837
- License Information
-
More Information
Article History
Received: 26 March 2021
Accepted: 6 September 2021
First Online: 17 September 2021
Declarations
:
: SAH: Contracted research funding paid to institution: Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd.; Travel support: Lilly (2019); Stock options: NK Max. HW: Institutional financial interest: consulting fees and honoraria to his institute from AstraZeneca, Biocartis, Lilly, Novartis, Pfizer, PUMA Biotechnology, Roche, Sirtex, Daiiji. Unrestricted research grants to his institute from Roche and Novartis. Travel support: Roche and Pfizer. The other authors declare that they have no conflict of interest.
: The Education-Support Committee (OBC) of the KU/UZ Leuven consented to the launch of this study. It judged that this study consisted in a pure literature study, and that this type of research does not require approval from a committee for medical ethics.
